The sweetest pill to swallow: How patient neurobiology can be harnessed to maximise placebo effects

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 10, 2013, Pages 2709-2720

  Jubb, Jayne ^a   Bensing, Jozien M ^a  

^a NETHERLANDS INSTITUTE FOR HEALTH SERVICES RESEARCH   (Netherlands)

Author keywords

Doctor patient communication; Dopamine; Expectancy; Neurobiology; Neuropsychology; Opioids; Placebo effect; Reward

Indexed keywords

CANNABINOID; DIAZEPAM; DOPAMINE; ENDOCANNABINOID; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PLACEBO; RIMONABANT;

ACUPUNCTURE; ANALGESIA; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL PRACTICE; COGNITION; CONDITIONING; DOCTOR PATIENT RELATION; DRUG PROTEIN BINDING; EXPECTATION; HUMAN; INTERPERSONAL COMMUNICATION; MEDICAL DECISION MAKING; MOTIVATION; NEUROPSYCHOLOGY; NEUROTRANSMISSION; NOCEBO EFFECT; PAIN; PILL; PLACEBO EFFECT; PRIORITY JOURNAL; REINFORCEMENT; REVIEW; REWARD;

AINS; ANTERIOR INSULA; CANNABINOID; CB; DA; DLPFC; DOCTOR-PATIENT COMMUNICATION; DOPAMINE; DORSAL STR.; DORSAL STRIATUM; DORSOLATERAL PREFRONTAL CORTEX; EXPECTANCY; INS; INSULA; NAC; NEUROBIOLOGY; NEUROPSYCHOLOGY; NUCLEUS ACCUMBENS; OFC; OPIOIDS; ORBITOFRONTAL CORTEX; PAG; PERIAQUEDUCTAL GREY; PET; PINS; PLACEBO EFFECT; POSITRON EMISSION TOMOGRAPHY; POSTERIOR INSULA; RACC; REWARD; ROSTRAL ANTERIOR CINGULATE CORTEX; SNR; STN; SUBSTANTIA NIGRA PARS RETICULATE; SUBTHALAMIC NUCLEUS; THAL; THALAMUS; V. STR.; VA; VENTRAL ANTERIOR THALAMUS; VENTRAL STRIATUM; VENTRAL TEGMENTAL AREA.; VENTROLATERAL THALAMUS; VLA; VTA;

ANALGESICS, OPIOID; CANNABINOIDS; CENTRAL NERVOUS SYSTEM; DOPAMINE; HUMANS; NEUROBIOLOGY; PLACEBO EFFECT;

EID: 84889686599     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.09.006     Document Type: Review

References (199)

1. Ader R., Mercurio M.G., Walton J., James D., Davis M., Ojha V., Kimball A.B., Fiorentino D. Conditioned pharmacotherapeutic effects: a preliminary study. Psychosom. Med. 2010, 72:192-197.
2. Amanzio M., Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J. Neurosci. 1999, 19:484-494.
3. Amanzio M., Pollo A., Maggi G., Benedetti F. Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain 2001, 90:205-215.
4. Amanzio M., Corazzini L.L., Vase L., Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009, 146:261-269.
5. Andrews G. Placebo response in depression: Bane of research, boon to therapy. Br. J. Psychiatry 2001, 178:192-194.
6. Andrykowski M.A., Otis M.L. Development of learned food aversions in humans: investigation in a 'natural laboratory' of cancer chemotherapy. Appetite 1990, 14:145-158.
7. Balint M. The Doctor: His Patient and The Illness 1957, Tavistock Publications, London.
8. Barrett B., Rakel D., Chewning B., Marchand L., Rabago D., Brown R., et al. Rationale and methods for a trial assessing placebo, echinacea, and doctor-patient interaction in the common cold. Explore 2007, 6:561.
9. Barsky A.J., Saintfort R., Rogers M.O., Borus J.F. Nonspecific medication side effects and the nocebo phenomenom. JAMA 2002, 287:622-627.
10. Bass M.J., Buck C., Turner L., Dickie G., Pratt G., Robinson H.C. The physician's actions and the outcome of illness in family practice. J. Family Practice 1986, 23:43-47.
11. Batterman R.C. Persistence of responsiveness with placebo therapy following an effective drug trial. J. Clin. Pharmacol. 1966, 6(3):137-141.
12. Batterman R.C., Lower W.R. Placebo responsiveness-influence of previous therapy. Curr. Therap. Res. Clin. Exp. 1968, 10:136-143.
13. Beecher H.K. The powerful placebo. JAMA 1955, 159:1602-1606.
14. Bendtsen L., Mattsson P., Zwart J.A., Lipton R.B. Placebo response in clinical randomized trials of analgesics in migraine. Cephalagia 2003, 23:487-490.
15. Benedetti F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 1996, 64:535-543.
16. Benedetti F. Cholecystokinin type-A and type-B receptors and their modulation of opioid analgesia. News Physiol. Sci. 1997, 12:263-268.
17. Benedetti F. No prefrontal control, no placebo response. Pain 2010, 148:357-358.
18. Benedetti F., Amanzio M., Maggi G. Potentiation of placebo analgesia by proglumide. Lancet 1995, 346:1231.
19. Benedetti F., Arduino C., Amanzio M. Somatotopic activation of opioid systems by target-directed expectations of analgesia. J. Neurosci. 1999, 19(9):3639-3648.
20. Benedetti F., Pollo A., Lopiano L., Lanotte M., Vighetti S., Rainero I. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J. Neurosci. 2003, 23:4315-4323.
21. Benedetti F., Maggi G., Lopiano L., Lanotte M., Rainero I., Vighetti S., et al. Open versus hidden medical treatments: The patient's knowledge about a therapy affects the therapy outcome. Prev. Treat. 2003, 6(1).
22. Benedetti F., Colloca L., Torre E., Lanotte M., Melcarne A., Pesare M., et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat. Neurosci. 2004, 7:587-588.
23. Benedetti F., Colloca L., Lanotte M., Bergamasco B., Torre E., Lopiano L. Autonomic and emotional responses to open and hidden stimulations of the human subthalamic region. Brain Res. Bull. 2004, 63:203-211.
24. Benedetti F., Mayberg H.S., Wager T.D., Stohler C.S., Zubieta J. Neurobiological mechanisms of the placebo effect. J. Neurosci. 2005, 25:10390-10402.
25. Benedetti F., Arduino C., Costa S., Vighetti S., Tarenzi L., Rainero I., et al. Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective. Pain 2006, 121:133-144.
26. Benedetti F., Amanzio M., Vighetti S., Asteggiano G. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J. Neurosci. 2006, 26:12014-12022.
27. Benedetti F., Lanotte M., Lopiano L., Colloca L. When words are painful-unraveling the mechanisms of the nocebo effect. Neuroscience 2007, 147:260-271.
28. Benedetti F., Pollo A., Colloca L. Opioid-mediated placebo responses boost pain endurance and physical performance: is it doping in sport competitions. J. Neurosci. 2007, 23:4315-4323.
29. Benedetti F., Lanotte M., Colloca L., Ducati A., Zibetti M., Lopiano L. Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response. J. Physiol. 2009, 587:3869-3883.
30. Benedetti F., Amanzio M., Rosato R., Blanchard C. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat. Med. 2011, 17:1228-1230.
31. Bensing J.M., Dronkers J. Instrumental and affective aspects of physician behavior. Med. Care 1992, 30:283-297.
32. Bensing J.M., Schreurs K., de Rijk A. The role of physician's affective behaviour in medical encounters. Psychol. Health 1996, 11:825-838.
33. Bensing J.M., Verheul W. The silent healer: The role of communication in placebo effects. Patient Educ. Couns. 2010, 80:293-299.
34. Berger J.T. Placebo medication use in patient care: a survey of medical interns. West. J. Med. 1999, 170(2):93-96.
35. Bernstein I.L. Aversion conditioning in response to cancer and cancer treatment. Clin. Psych. Revs. 1991, 11:185-191.
36. Bernstein C.N. The placebo effect for gastroenterology: tool or torment. Clin. Gastroenterol. Hepatol. 2006, 4:1302-1308.
37. Bingel U., Lorenz J., Schoell E., Weiller C., Buchel C. Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain 2006, 120:8-15.
38. Bingel U., Wanigasekera V., Wiech K., Mhuircheartaigh R.N., Lee M.C., Ploner M., Tracey I. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci. Trans. Med. 2011, 3. 70ra14.
39. Bradford A., Meston C. Correlates of placebo response in the treatment of sexual dysfunction in women: a preliminary report. J. Sex. Med. 2007, 4:1345-1351.
40. Branthwaite A., Cooper P. Analgesic effects of branding in treatment of headaches. Br. Med. J. (Clin. Res. Ed.) 1981, 282(6276):1576-1578.
41. Breton J.D., Veinante P., Uhl-Bronner S., Vergnano A.M., Freund-Mercier M.J., Schlichter R., et al. Oxytocin-induced antinociception in the spinal cord is mediated by a subpopulation of glutamatergic neurons in lamina I-II which amplify GABAergic inhibition. Mol. Pain 2008, 4:19.
42. Brody H. The doctor as therapeutic agent: a placebo effect research agenda. The Placebo Effect: An Interdisciplinary Exploration 1997, 77-92. Harvard University Press, Cambridge, MA. A. Harrington (Ed.).
43. Brody H. Medicine's continuing quest for an excuse to avoid relationships with patients. Am. J. Bioeth. 2009, 9:13-15.
44. Brunoni A.R., Lopes M., Kaptchuk T.J., Fregni F. Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS ONE 2009, 4:e4824.
45. Buckalew L.W., Ross S. Relationship of perceptual characteristics to efficacy of placebos. Psychol. Rep. 1981, 49(3):955-961.
46. Chvetzoff G., Tannock I.F. Placebo effects in oncology. J. Nat. Cancer Inst. 2003, 95:19-29.
47. Clayton A.H., West S.G., McGarvery E., Leslie C., Keller A. Biochemical evidence of the placebo effect during the treatment of menstrual migraines. J. Clin. Psychopharmacol. 2005, 25:400-401.
48. Cobb L.A., Thomas G.I., Dillard D.H., Merendino K.A., Bruce R.A. An evaluation of internal mammary artery ligation by double-blind technique. New Eng. J. Med. 1959, 260:1115-1118.
49. Colloca L., Lopiano L., Lanotte M., Benedetti F. Overt versus covert treatment for pain, anxiety, and Parkinson's disease. Lancet Neurol. 2004, 3:679-684.
50. Colloca L., Benedetti F. Placebos and painkillers: is mind as real as matter?. Nat. Rev. Neurosci. 2005, 6:545-552.
51. Colloca L., Benedetti F. How prior experience shapes placebo analgesia. Pain 2006, 124:126-133.
52. Crow R., Gage H., Hampson S., Hart J., Kimber A., Thomas H. The role of expectancies in the placebo effect and their use in the delivery of health care: A systematic review. Health Technol. Assess. 1999, 3(3):1-96.
53. de Craen A.J., Roos P.J., Leonard de Vries A., Kleijnen J. Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness. BMJ 1996, 313(7072):1624-1626.
54. de Craen A.J., Kaptchuk T.J., Tijssen J.G., Kleijnen J. Placebos and placebo effects in medicine: historical overview. J. R. Soc. Med. 1999, 92(10):511-515.
55. de Craen A.J.M., Tijssen J.G.P., de Gans J., Kleijnen J. Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. J. Neurol. 2000, 247:183-188.
56. de Haes H., Bensing J.M. Endpoints in medical communication research, proposing a framework of functions and outcomes. Patient Educ. Couns. 2009, 74(3):287-294.
57. de la Fuente-Fernández R., Ruth T.J., Sossi V., Schulzer M., Calne D.B., Stoessl A.J. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001, 293:1164-1166.
58. de la Fuente-Fernández R., Phillips A.G., Zamburlini M., Sossi V., Calne D.B., Ruth T.J., et al. Dopamine release in human ventral striatum and expectation of reward. Behav. Brain Res. 2002, 136:359-363.
59. de la Fuente-Fernandez R., Stoessl A.J. The placebo effect in Parkinson's disease. Trends Neurosci. 2002, 25:302-306.
60. de la Fuente-Fernandez R., Schulzer M., Stoessl A.J. Placebo mechanisms and reward circuitry: clues from parkinson's disease. Biol. Psychiatry 2004, 56:67-71.
61. Di Blasi Z., Harkness E., Ernst E., Georgiu A., Kleijnen J. Influence of context effects on health outcomes: a systematic review. Lancet 2001, 357:757-762.
62. Diener H.C. Effcacy and safety of intravenous acetylsalicyclic acid lysinate compared to subcutaneous sumatripan and parenteral placebo in the acute treatment of migraine. A double-blind, double dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Cephalagia 1999, 19:581-588.
63. Dimond E.G., Kittle C.F., Crockett J.E. Evaluation of internal mammary ligation and sham procedure in angina pectoris. Circulation 1958, 18:712-713.
64. Enck P., Klosterhalfen S. The placebo response in functional bowel disorders: perspectives and putative mechanisms. Neurogastroenterol. Motil. 2005, 17:325-331.
65. Enck P., Klosterhalfen S. The story of O-is oxytocin the mediator of the placebo response?. Neurogastroenterol. Motil. 2009, 21:347-350.
66. Engel G.L. How much longer must medicine's science be bound by a seventeenth century world view. The Task of Medicine: Dialogue at Wickenburg 1988, 113-136. The Henry Kaiser Foundation, Menlo Park, USA. K. White (Ed.).
67. Epstein, R.M., Street, R.L.J., 2007. Patient-centered communication in cancer care:promoting healing and reducing suffering. NIH Publication No. 07-6225.
68. Ferrari M.D., Roon K.I., Lipton R.B., Goadsby P.J. Oral triptans (serotonin 5-HT 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001, 358:1668-1675.
69. Fink H.A., MacDonald R., Rutks I.R., Nelson D.B., Wilt T.J. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch. Intern. Med. 2002, 162:1349-1360.
70. Finniss D.G., Benedetti F. Mechanisms of the placebo response and their impact on clinical trials and clinical practice. Pain 2005, 114:3-6.
71. Finniss D.G., Kaptchuk T.J., Miller F., Benedetti F. Biological, clinical, and ethical advances of placebo effects. Lancet 2010, 375:686-695.
72. Flaten M.A., Simonsen T., Olsen H. Mechanisms of the placebo response and their impact on clinical trials and clinical practice. Pain 1991, 114:3-6.
73. Fowler C.J. The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. Br. J. Pharmacol. 2007, 152:594-601.
74. Fratello F., Curcio G., Ferrara M., Marzano C., Couyoumdjian A., Petrillo G., et al. Can an inert sleeping pill affect sleep? Effects on polysomnographic, behavioural and subjective measures. Psychopharmacology 2005, 181:761-770.
75. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 2001, 344:710-719.
76. Fricchione G., Stefano G.B. Placebo neural systems: nitric oxide, morphine and the dopamine brain reward and motivation circuitries. Med. Sci. Monit. 2005, 11:MS54-MS65.
77. Garris P.A., Kilpatrick M., Bunin M.A., Michael D., Walker Q.D., Wightman R.M. Dissociation of dopamine release in the nucleus accumbens from intracranial self-stimulation. Nature 1999, 398:67-69.
78. Geuter S., Eippert F., Hindi Attar C., Buchel C. Cortical and subcortical responses to high and low effective placebo treatments. Neuroimage 2013, 67:227-236.
79. Goebel M.U., Trebst A.E., Steiner J., Xie Y.F., Exton M.S., Frede S., et al. Behavioural conditioning of immunosuppression is possible in humans. FASEB J. 2002, 16:1869-1873.
80. Goebel M.U., Hubell D., Kou W., Janssen O.E., Katsarava Z., Limmroth V., et al. Behavioural conditioning with interferon beta-1a in humans. Physiol. Behav. 2005, 84:807-814.
81. Goebel M.U., Meykadeh N., Kou W., Schedlowski M., Hengge U.R. Behavioural conditioning of antihistamine effects in patients with allergic rhinitis. Psychother. Psychosom. 2009, 77:227-234.
82. Goetz C.G., Leurgans S., Raman R., Stebbins G.T. Objective changes in motor function during placebo treatment in PD. Neurology 2000, 54:710.
83. Gracely R.H., Dubner R., Wolskee P.J., Deeter W.R. Placebo and naloxone can alter post-surgical pain by separate mechanisms. Nature 1983, 306:264-265.
84. Greenberg L.M., Roth S. Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients. Am. J. Psychol. 1966, 123:221-226.
85. Greenfield S., Kaplan S., Ware J.E. Expanding patient involvement in care. Ann. Intern. Med. 1985, 102:520-528.
86. Grevert P., Albert L., Goldstein A. Partial antagonism of placebo analgesia by naloxone. Pain 1983, 16:129-143.
87. Henry P., Hiesse-Provost O., Dillenschneider A., Ganry H., Insuasty J. Efficacy and tolerance of an effervescent aspirin-metoclopramide combination in the treatment of a migraine attack. Randomized double-blind study using a placebo. Presse Med. 1995, 24(5):254-258.
88. Hrobjartsson A., Gøtzsche P.C. Is the placebo effect powerless? An analysis of clinical trials comparing placebo with no treatment. N. Engl. J. Med. 2001, 344:1594-1602.
89. Hrobjartsson A., Norup M. The use of placebo interventions in medical practice - A national questionnaire survey of Danish clinicians. Eval. Health Prof. 2003, 26(2):153-165.
90. Hrobjartsson A., Gøtzsche P.C. Is the placebo effect powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J. Int. Med. 2004, 256:91-100.
91. Hrobjartsson, A., Gøtzsche, P.C., 2004b. Placebo interventions for all clinical conditions. Cochrane Database of Systematic Reviews Issue 2 Art No: CD003974.
92. Hrobjartsson A., Gøtzsche P.C. Unsubstantiated claims of large effects of placebo on pain: serious errors in meta-analysis of placebo analgesia mechanism studies. J. Clin. Epidemiol. 2006, 59:336-338.
93. Hrobjartsson, Gøtzsche Powerful spin in the conclusion of Wampold et al's re-analysis of placebo versus no-treatment trials despite similar results as in original review. J. Clin. Psychol. 2007, 63(4):373-377.
94. Hrobjartsson A., Gøtzsche P.C. Wampold et al's reiterate spin in the conclusion of a re-analysis of placebo versus no-treatment trials despite similar results as in original review. J. Clin. Psychol. 2007, 63(4):405-408.
95. Hrobjartsson, A., Gøtzsche, P.C., 2010. Placebo interventions for all clinical conditions. Cochrane Database of Systematic Reviews Issue 1 Art No: CD003974.
96. Hróbjartsson A., Kaptchuk T.J., Miller F.G. Placebo effect studies are susceptible to response bias and to other types of biases. J. Clin. Epidemiol. 2011, 64:1223-12239.
97. Husten L. Fetal-cell-implantation trial yields mixed results. Lancet 1999, 353:1501.
98. Jacobsen P.B., Bovbjerg D.H., Schwartz M.D., Andrykowskim M.A., Futterman A.D., Gilewski T., et al. Formation of food aversions in cancer patients receiving repeated infusions of chemotherapy. Behav. Res. Ther. 1993, 31:739-748.
99. Jensen K.B., Kaptchuk T.J., Kirsch I., Raicek J., Lindstrome K.M., Berna C., Gollub R.L., Ingvare M., Kong J. Nonconscious activation of placebo and nocebo responses. PNAS 2012, 109:15959-15964.
100. Jensen K.B., Petrovic P., Kerr C., Kirsch I., Raicek J., Cheetham A., Spaeth R., Cook A., Gollub R.L., Kong J., Kaptchuk T.J. Sharing pain and relief: neural correlates of physicians during treatment of patients. Mol. Psychol. 2013, doi: 10.1038/mp.2012.195.
101. Kaptchuk T. Powerful placebo: The dark-side of the randomized controlled trial. Lancet 1998, 351:1722.
102. Kaptchuk T.J., Goldman P., Stone D.A., Stason W.B. Do medical devices have enhanced placebo effects?. J. Clin. Epidemiol. 2000, 53:786-792.
103. Kaptchuk T.J., Stason W.B., Davis R.B., Legedza A.R., Schnyer R.N., Kerr C.E., et al. Sham device v inert pill: randomised controlled trial of two placebo treatments. BMJ 2006, 332:391-397.
104. Kaptchuk T.J., Shaw J., Kerr C.E., Conboy L.A., Kelley J.M., Csordas T.J., et al. Maybe i made up the whole thing": placebos and patients' experiences in a randomized controlled trial. Cult. Med. Psychiatry 2009, 33:382-411.
105. Kaptchuk T.J., Friedlander E., Kelley J.M., Sanchez M.N., Kokkotou E., Singer J.P., Kowalczykowski M., Miller F.G., Kirsch I., Lembo A.J. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010, 5:e15591.
106. Kelley A.E., Berridge K.C. The neuroscience of natural rewards: relevance to addictive drugs. J. Neurosci. 2002, 22:3306-3311.
107. Kelley J.M., Lembo A.J., Ablon J.S., Villanueva J.J., Conboy L.A., Levy R., et al. Patient and practitioner influences on the placebo effect in irritable bowel syndrome. Psychosom. Med. 2009, 71:789-797.
108. Khan A., Warner H.A., Brown W.A. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the FDA database. Arch. Gen. Psychiatry 2000, 57:311-317.
109. Kirsch I. Response expectancy as a determinant of experience and behavior. Am. Psychol. 1985, 40:1189-1202.
110. Kirsch I. Conditioning, expectancy, and the placebo effect: comment on Stewart-Williams and Pod. Psychol. Bull. 2004, 130(2):341-342.
111. Kirsch I., Deacon B.J., Huedo-Medina T.B., Scoboria A., Moore T.J., Johnson B.T. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008, 5:e45.
112. Klosterhalfen S., Kelerman S., Stockhorst U., Wolf J., Kirschbaum C., Hall G., et al. Latent inhibition of rotation chair-induced nausea in healthy male and female volunteers. Psychosom. Med. 2005, 67(2):335-340.
113. Kong J., Gollub R.L., Rosman I.S., Webb J.M., Vangelm M.G., Kirsch I., et al. Brain activity associated with expectancy-enhanced placebo analgesia as measured by functional magnetic resonance imaging. J. Neurosci. 2006, 26:381-388.
114. Krummenacher P., Candia V., Folkers G., Schedlowski M., Schönbächler G. Prefrontal cortex modulates placebo analgesia. Pain 2010, 148:368-374.
115. Lang E.V., Hatsiopoulou O., Koch T., Berbaum K., Lutgendorf S., et al. Can words hurt? Patient-provider interactions during invasive procedures. Pain 2005, 114:303-309.
116. Lanotte M., Lopiano L., Torre E., Bergamasco B., Colloca L., Benedetti F. Expectation enhances autonomic responses to stimulation of the human subthalamic limbic region. Brain Behav. Immun. 2005, 19:500-509.
117. Laska E., Sunshine A. Anticipation of analgesia: a placebo effect. Headache 1973, 13:1-11.
118. Last J.M. Dictionary of Epidemiology 1983, Oxford University Press, New York.
119. Leuchter A.F., Cook I.A., Witte E.A., Morgan M., Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am. J. Psychiatry 2002, 159:122-129.
120. Levine J.D., Gordon N., Fields H. The mechanism of placebo analgesia. Lancet 1978, 2:654-657.
121. Levine J.D., Gordon N.C., Smith R., Fields H.L. Analgesic response to morphine and placebo individuals with postoperative pain. Pain 1981, 10:379-389.
122. Levine J.D., Gordon N.C. Influence of the method of drug administration on analgesic response. Nature 1984, 312:755-756.
123. Lichko A.E. Conditioned reflex hypoglycemia in man. Pavlov. J. High Nerv. Activity 1959, 9:731-737.
124. Macedo A., Farre M., Banos J.E. A meta-analysis if the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials. Eur. J. Clin. Pharmacol. 2006, 62:161-172.
125. Mayberg H.S., Silva J.A., Brannan S.K., Tekell J.L., Mahurin R.K., McGinnis S., et al. The functional neuroanatomy of the placebo effect. Am. J. Psychiatry 2002, 159:728-737.
126. McCall W.V., D'Agostino R., Dunn A. A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials. Sleep Med. 2003, 4:57-62.
127. McConnell J.D., Bruskewitz R., Walsh P., Andriole G., Lieber M., Holtgrewe H.L., et al. The effects of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. New Eng. J. Med. 1998, 338:557-563.
128. McRae C., Cherin E., Yamazaki T.G., Diem G., Vo A.H., Russell D., et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch. Gen. Psychiatry 2004, 61:412-420.
129. Mercado R., Constantoyannis C., Mandat T., Kumar A., Schulzer M., Stoessl A.J., et al. Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. Mov. Disord. 2006, 21:1457-2161.
130. Mondaini N., Gontero P., Giubilei G., Lombardi G., Cai T., Gavazzi A., et al. Finasteride 5mg and sexual side effects: how many of these are related to a nocebo phenomenon?. J. Sex. Med. 2007, 4:1708-1712.
131. Morrish P.K., Sawle G.V., Brooks D.J. An [l8F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996, 119:585-591.
132. Moseley J.B., O'Malley K., Petersen N.J., Menke T.J., Brody B.A., Kuykendall D.H., et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. New Eng. J. Med. 2002, 347:81-88.
133. Moyad M.A. The placebo effect and randomized trials: analysis of conventional medicine. Urol. Clin. North Am. 2002, 29:125-133.
134. Musial F., Klosterhalfen S., Enck P. Placebo responses in patients with gastrointestinal disorders. World J. Gastroenterol. 2007, 13:3425-3429.
135. Nesse R.M., Carli T., Curtis G.C., Kleinman P.D. Pretreatment nausea in cancer chemotherapy: a conditioned response?. Psychosom. Med. 1980, 42:33-36.
136. Neumann M., Bensing J., Wirtz M., Wubker A., Scheffer C., Tauschel D., Edelhauser F., Ernstman N., Pfaff H. The impact of financial incentives on physician empathy: A study from the perspective of patients with private and statutory health insurance. Patient Educ. Couns. 2010, 84:208-216.
137. Nickel J.C. Placebo therapy of benign prostrate hyperplasia: a 25-month study. Canadian PROSPECT Study Group. Br. J. Urol. 1998, 81:383-387.
138. Nitzan U., Lichtenberg P. Questionnaire survey on use of placebo. BMJ 2004, 329:944-946.
139. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54:403-414.
140. Olness K., Ader R. Conditioning as an adjunct in the pharmacotherapy of lupus erythematosus. J. Dev. Behav. Pediatr. 1992, 13:124-125.
141. Petrovic P., Kalso E., Petersson K.M., Ingvar M. Placebo and opioid analgesia imaging a shared neuronal network. Science 2002, 295:1737-1740.
142. Petrovic P., Dietrich T., Fransson P., Andersson J., Carlsson K., Ingvar M. Placebo in emotional processing-induced expectations of anxiety relief activate a generalized modulatory network. Neuron 2005, 46:957-969.
143. Pollo A., Torre E., Lopiano L., Rizzone M., Lanotte M., Cavanna A., et al. Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. Neuroreport 2002, 13:1383-1386.
144. Pollo A., Carlino E., Benedetti F. The top-down influence of ergogenic placebos on muscle work and fatigue. Eur. J. Neurosci. 2008, 28:379-388.
145. Pollo A., Carlino E., Vase L., Benedetti F. Preventing motor training through nocebo suggestions. Eur. J. Appl. Physiol. 2012, 112(11):3893-3903.
146. Price D.D., Milling L.S., Kirsch I., Duff A., Montgomery G.H., Nicholls S.S. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain 1999, 83:147-156.
147. Price D.D., Finniss D.G., Benedetti F.A. Comprehensive Review of the Placebo Effect: Recent Advances and Current Thought. Annu. Rev. Psychol. 2008, 59:565-590.
148. Raicek J., Stone B.H., Kaptchuk T.J. Placebos in 19th century medicine: a quantitative analysis of the BMJ. BMJ 2012, 345:38326.
149. Rana J.S., Mannam A., Donnell-Fink L., Gervino E.V., Sellke F.W., Laham R.J. Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. Am. J. Cardiol. 2005, 95:1456-1459.
150. Raz A., Fan J., Posner M.I. Hypnotic suggestion reduces conflict in the human brain. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9978-9983.
151. Rief W., Nestoriuc Y., Weiss S., Welzel E., Barsky A.J., Hofmann S.G. Meta-analysis of the placebo response in antidepressant trials. J. Affect. Disord. 2009, 118:1-8.
152. Roberts A.H., Kewman D.G., Mercier L., Hovell M. The power of nonspecific effects in healing: implications for psychological and biological treatments. Clin. Psychol. Rev. 1993, 13:375-391.
153. Roscoe J.A., Morrow G.R., Hickok J.T., Bushunow P., Pierce H.I., Flynn P.J., et al. The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting: a URCC CCOP multicenter study. J. Pain Symptom Manage. 2003, 26:731-742.
154. Roscoe J.A., O'Neill M., Jean-Pierre P., Heckler C.E., Kaptchuk T.J., Bushunow P., et al. An exploratory study on the effects of an expectancy manipulation on chemotherapy-related nausea. J. Pain Symptom Manage. 2010, 40(3):379-390.
155. Rosseland L.A., Helgesen K.G., Breivik H., Stubhaug A. Moderate-to-severe pain after knee arthroscopy is relieved by intraarticular saline: a randomized controlled trial. Anesth. Analg. 2004, 98:1546-1551.
156. Roter D.L., Hall J.A. Doctors Talking With Patients/Patients Talking With Doctors: Improving Communication in Medical Visits 2006, Praeger Publishers, Westport, CT, USA.
157. Roter D.L., Frankel R.M., Hall J.A., Sluyter D. The expression of emotion through nonverbal behavior in medical visits. Mechanisms and outcomes. J. Gen. Intern. Med. 2006, 21(Suppl. 1):S28-S34.
158. Rouzer C.A., Marnett L.J. Non-redundant functions of cyclooxygenases: oxygenation of endocannabinoids. J. Biol. Chem. 2008, 283:8065-8069.
159. Sandler A.D., Glesne C.E., Bodfish J.W. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder?. J. Dev. Behav. Pediatr. 2010, 31:369-375.
160. Scott D.J., Stohler C.S., Egnatuk C.M., Wang H., Koeppe R.A., Zubieta J.K. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch. Gen. Psychiatry 2008, 65:220-231.
161. Shapiro A.K., Shapiro E. The Powerful Placebo: From Ancient Priest to Modern Physician 1997, Johns Hopkins University Press, Baltimore, USA.
162. Sherman R.C., Hickner J. Physicians use placebos in clinical practice and believe in the mind-body connection. J. Gen. Int. Med. 2007, 22:97.
163. Shetty N., Friedman J.H., Kieburtz K., Marshall F.J., Oakes D. The placebo response in Parkinson's disease. Clin. Neuropharmacol. 1999, 22:207.
164. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 2009, 49:123-150.
165. Starfield B., Wray C., Hess K., Gross R., Birk P.S., D'Lugoff B.C. The influence of patient-practitioner agreement on outcome of care. Am. J. Publ. Health 1981, 71:127-132.
166. Stefano G.B., Fricchione G.L., Slingsby B.T., Benson H. The placebo effect and relaxation response: neural processes and their coupling to constitutive nitric oxide. Brain Res. Rev. 2001, 35:1-19.
167. Stewart M.A., McWhinney I.R., Buck C.W. The doctor-patient relationship and its effect upon outcome. J. R. Coll. Gen. Pract. 1979, 29:77-82.
168. Stewart M.A. Effective physician-patient communication and health outcomes: a review. Can. Med. Assoc. J. 1995, 152:1423-1433.
169. Stewart-Williams S., Podd J. The placebo effect: dissolving the expectancy versus conditioning debate. Psychol. Bull. 2004, 130(2):324-340.
170. Stockhorst U., Wiener J.A., Klosterhalfen S., Klosterhalfen W., Aul C., Steingrueber H.J. Effects of overshadowing on conditioned nausea in cancer patients: an experimental study. Physiol. Behav. 1998, 64:743-753.
171. Stockhorst U., Gritzmann E., Klopp K., Schottenfeld-Naor Y., Hübinger A., Berresheim H.W., et al. Classical conditioning of insulin effects in healthy humans. Psychosom. Med. 1999, 61:424-435.
172. Stockhorst U., Spennes-Saleh S., Körholz D., Göbel U., Schneider M.E., Steingrüber H.J., et al. Anticipatory symptoms and anticipatory immune responses in pediatric cancer patients receiving chemotherapy: features of a classically conditioned response?. Brain Behav. Immun. 2000, 14:198-218.
173. Stockhorst U., Steingrueber H.J., Enck P., Klosterhalfen S. Pavlovian conditioning of nausea and vomiting. Autonom. Neurosci. 2006, 129:50-57.
174. Stockhorst U., Enck P., Klosterhalfen S. Role of classical conditioning in learning gastrointestinal symptoms. World J. Gastroent. 2007, 13:3430-3437.
175. Strafella A.P., Ko J.H., Monchi O. Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: The contribution of expectation. Neuroimage 2006, 31:1666-1672.
176. Sunshine A., Laska E., Meisner M., Morgan S. Analgesic studies of indomethacin as analyzed by computer techniques. Clin. Pharmacol. Ther. 1964, 5:699-707.
177. Tfelt-Hansen P., Henry P., Mulder L.J., Schaeldewaert R.G., Schoenen J., Chazot G. The effectiveness of the combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995, 346:923-926.
178. Tilburt J.C., Emanuel E.J., Kaptchuk T.J., Curlin F.A., Miller F.G. Prescribing "placebo treatments": results of national survey of US internists and rheumatologists. BMJ 2008, 337:a1938.
179. Tobler P.N., Fiorillo C.D., Schultz W. Adaptive coding of reward value by dopamine neurons. Science 2005, 307:1642-1645.
180. Tyc V.L., Mulhem R.K., Barclay D.R., Smith B.F., Bieberich A.A. Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron anti-emetic therapy. J. Pediatr. Psychol. 1997, 22:45-58.
181. van Dulmen A.M., Bensing J.M. The effect of context in healthcare a programming study 2001, vol. 3. RGO, The Hague, ISBN 9014655-5.
182. van Leeuwen J.H.S., Castro R., Busse M., Bemelmans B.L.H. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur. Urol. 2006, 50:440-452.
183. Vase L., Riley J.L., Price D.D. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain 2002, 99:443-452.
184. Vase L., Robinson M.E., Verne G.N., Price D.D. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation. Pain 2003, 105:17-25.
185. Vase L., Robinson M.E., Verne G.N., Price D.D. Increased placebo analgesia over time in irritable bowel sundrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain 2005, 115:338-347.
186. Vase L., Petersen G.L., Riley J.L., Price D.D. Factors contributing to large analgesic effects in placebo mechanism studies conducted between 2002 and 2007. Pain 2009, 145:36-44.
187. Verheul W., Sanders A., Bensing J. The effects of physicians' affect-oriented communication style and raising expectations on analogue patients' anxiety, affect and expectancies. Patient Educ. Couns. 2010, 80:300-306.
188. Verne G.N., Robinson M.E., Vase L., Price D.D. Reversal of visceral and cutaneous hyperalgesia by local rectal anesthesia in irritable bowel syndrome (IBS) patients. Pain 2003, 105:223-230.
189. Volkow N.D., Wang G.J., Ma Y., Fowler J.S., Zhu W., Maynard L., et al. Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. J. Neurosci. 2003, 23:11461-11468.
190. Waber R.L., Shiv B., Carmon Z., Ariely D. Commercial features of placebo and therapeutic efficiency. J. Am. Med. Assoc. 2008, 299:1016-1017.
191. Wager T.D., Rilling J.K., Smith E.E., Sokolik A., Casey K.L., Davidson R.J., et al. Placebo-induced changes in fMRI in the anticipation and experience of pain. Science 2004, 303:1162-1167.
192. Walsh J.K., Roth T., Randazzo A., Erman M., Jamieson A., Scharf M., et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000, 23:1087-1096.
193. Walsh B.T., Seidman S.N., Sysko R., Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002, 287:1840-1847.
194. Walter H., Abler B., Ciaramidaro A., Erk S. Motivating forces of human actions: Neuroimaging reward and social interaction. Brain Res. Bull. 2005, 67:368-381.
195. Wells R., Kaptchuk T.J. To tell the truth, the whole truth, may do patients harm: The problem of the nocebo effect for informed consent. Am. J. Bioethics 2012, 12(3):22-29.
196. White K.L. The Task of Medicine: Dialogue at Wickenburg 1988, H.J. Kaiser Family Foundation.
197. Yang J., Yang Y., Chen J.M., Liu W.Y., Wang C.H., Lin B.C. Effect of oxytocin on acupuncture analgesia in the rat. Neuropeptides 2007, 41:285-292.
198. Zubieta J.K., Bueller J.A., Jackson L.R., Scott D.J., Xu Y., Koeppe R.A., et al. Placebo effects mediated by endogenous opioid activity on μ-opioid receptors. J. Neurosci. 2005, 25:7754-7762.
199. Zubieta J.K., Yau W.Y., Scott D.J., Stohler C.S. Belief or need? Accounting for individual variations in the neurochemistry of the placebo effect. Brain Behav. Immun. 2006, 20:15-26.